Exact Sciences Intrinsic Value – Exact Sciences Corp shares drop by 3.11% in mid-day trading on Oct 21
October 26, 2024
🌥️Trending News
Exact Sciences ($NASDAQ:EXAS) Corp is a leading biotechnology company that specializes in developing non-invasive cancer screening tests. Their flagship product, Cologuard, is a non-invasive stool-based DNA test that is used to detect colorectal cancer. The company’s mission is to “detect cancer early when it’s most treatable.” On October 21, Exact Sciences Corp’s shares experienced a 3.11% decline during mid-day trading. The decline in share price can be attributed to a number of factors, including overall market conditions and company-specific news. One possible reason for the decline in Exact Sciences Corp’s shares could be the release of their third-quarter earnings report. The company’s earnings fell short of analyst expectations, causing investors to sell off their shares. This disappointment may have also been reflected in the company’s decreased revenue guidance for the rest of the year. Another factor that may have contributed to the drop in share price is the overall performance of the healthcare sector. The healthcare sector has been experiencing volatility in recent months due to concerns about potential changes in government policies and regulations. As a result, many healthcare stocks, including Exact Sciences Corp’s, have been affected by this uncertainty. Despite the decline in share price, Exact Sciences Corp remains a strong player in the biotechnology industry. The company has seen significant growth over the years, with its stock value more than doubling in the last five years.
Additionally, their flagship product, Cologuard, has seen a steady increase in demand and has been approved by major insurance providers. This suggests that the company still has potential for long-term growth and success. As a leading biotechnology company in the cancer screening market, Exact Sciences Corp remains a strong player in the industry with potential for long-term growth. Investors should continue to monitor the company’s performance and industry trends before making any investment decisions.
Analysis – Exact Sciences Intrinsic Value
As an investment analyst at GoodWhale, I have conducted a thorough analysis of EXACT SCIENCES, a medical diagnostics company. In order to determine the fair value of EXACT SCIENCES shares, I have examined the company’s underlying principles and evaluated its financials and market trends. Based on my analysis, I have determined that the fair value of EXACT SCIENCES share is approximately $88.9, which represents a 20.6% discount from its current trading price of $70.58. One of the key factors contributing to EXACT SCIENCES’s strong financial standing is its underlying principles. The company is focused on providing accurate and non-invasive cancer screening tests, which have a growing demand in the healthcare industry. Additionally, EXACT SCIENCES has a strong commitment to innovation and research, continuously developing new and advanced technologies to improve their products and services. This growth is expected to continue as the company expands its market reach and introduces new products. Moreover, EXACT SCIENCES has a solid balance sheet with low debt levels and strong cash reserves, providing stability and flexibility for future investments and acquisitions. Market trends also support the potential for growth in EXACT SCIENCES’s stock value. The rising prevalence of cancer globally, combined with a shift towards early detection and personalized medicine, creates a favorable environment for the company’s products and services. Taking all these factors into consideration, my valuation method using our proprietary Valuation Line suggests that EXACT SCIENCES’s shares are currently undervalued. This means that there is potential for upside in the stock price, making it an attractive investment opportunity for long-term investors. In conclusion, EXACT SCIENCES’s strong underlying principles, solid financials, and favorable market trends indicate that the company has a promising future. With a fair value of $88.9 and a current trading price of $70.58, there is a clear opportunity for investors to capitalize on the undervalued stock. As an analyst at GoodWhale, I believe that EXACT SCIENCES presents a compelling investment opportunity for those seeking long-term growth potential in the medical diagnostics industry. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exact Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 2.5k | -204.15 | -9.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exact Sciences. More…
| Operations | Investing | Financing |
| 156.12 | 49.68 | 159.77 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exact Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.47k | 3.33k | 17.34 |
Key Ratios Snapshot
Some of the financial key ratios for Exact Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.8% | – | -7.1% |
| FCF Margin | ROE | ROA |
| 1.3% | -3.5% | -1.7% |
Peers
The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.
Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.
– Myriad Genetics Inc ($NASDAQ:MYGN)
Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.
Summary
On October 21, shares of Exact Sciences Corp experienced a 3.11% decrease in mid-day trading. The stock hit a low of $69.52 before showing a slight recovery. This decline could be attributed to several factors, including overall market trends and investor sentiment towards the company. Investors should closely monitor the stock’s performance in the coming days to determine if this was a temporary dip or a larger trend.
Conducting further analysis on the company’s financials, industry trends, and potential upcoming developments can help inform investment decisions. It is important to carefully consider all factors before making any investment decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
